PledPharma AB is a pharmaceutical company based in Sweden that focuses on developing innovative pharmaceutical products to treat severe illnesses. Their flagship drug, PledOx, is currently in Phase IIb clinical trials and aims to minimize the harmful side effects of chemotherapy in patients with colorectal cancer. Additionally, PledPharma has a project pipeline that includes Aladote (PP-100), which is undergoing Phase II clinical trials to address acute liver failure caused by acetaminophen poisoning, and PP-099, a drug candidate that has completed Phase IIa clinical trials for the treatment of acute myocardial infarction. PledPharma's primary objective is to create medications that protect the body from oxidative stress, a potentially debilitating and life-threatening condition triggered by chemotherapy and acetaminophen overdose. PledOx, their most advanced project, has shown promising results in reducing nerve damage associated with chemotherapy, and further development is planned based on the phase IIb study. Another drug candidate, Aladote, aims to decrease the risk of acute liver failure resulting from acetaminophen poisoning. PledPharma is listed on Nasdaq First North under the ticker symbol STO: PLED.